BRL-303

N/A

Report date: 2026/03/16 20:01:47

Base Information

Drug NameBRL-303
Drug Alias Name靶向CD19基因修饰的异体嵌合抗原受体T细胞注射液BRL-303
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBRL Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesBRL Medicine Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A